Wikipedia -WSS

Wikipedia

author：comprehensive 2025-09-30 00:37:29 - browse：29676

Stock illustration of computer and medication — Adobe

Digital therapeutics company Click Therapeutics announced Wednesday it will acquire the assets of Better Therapeutics, developer of a software-based treatment for diabetes. Click, which did not disclose how much it is paying for the assets, hopes to adapt Better’s tech for use alongside GLP-1 medications.

Better Therapeutics announced in March that it was delisting from the Nasdaq stock exchange and shutting down operations as it sought strategic alternatives. The company had been, since last year, searching for ways to stay afloat as its cash reserves dwindled.

Last, year, Better received Food and Drug Administration clearance for AspyreRx, a prescription app that delivers cognitive behavioral therapy and had been shown to reduce A1c levels in people with type 2 diabetes. Still, the company has been unable to ramp up significant commercial traction. Better also had a pipeline of other products targeting cardiometabolic conditions, and had made early claims about the benefits of AspyreRx in people taking GLP-1s for diabetes management.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： FDA seeks to regulate lab

WSS

Would Medicare drug price negotiations stall in a shutdown?

Did you have Obamacare on your GOP debate bingo card?

Researchers use wearables data and AI to predict preterm birth risk

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

How the Dana

FDA advisers vote against ALS treatment from BrainStorm

leisure time

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

focus

Medical leaders decry Supreme Court decision on affirmative action

Kaiser Permanente unions announce official strike date

After affirmative action ruling, medical educators look to 'holistic review'

Congress must reauthorize a committee to support older Americans

At least 13 dead in Texas as scorching temps continue

FDA's Woodcock to retire early next year

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Biogen shutters digital health group, ends Apple study, in cost cutting move

Novavax promises a turnaround & Lilly roils the obesity market

Kaiser Permanente unions announce official strike date

knowledge

Morphosys mixed study results for blood cancer drug

Weight loss drug costs may need more research, senator suggests

Anthos stroke drug appears safer than common blood thinner

Astellas still sees hope in its gene therapy after four deaths

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Cigna to pay $172 million to settle Medicare Advantage fraud probe

focus

explore

entertainment

focus